

CINQAIR (reslizumab) Injection Cost Support Program Terms and Conditions:

- This CINQAIR Cost Support Program (the “Program”) helps commercially insured individuals in the United States (including the United States territories) who are prescribed CINQAIR (reslizumab) pay for their eligible out-of-pocket costs for the drug and for administration of the drug, including co-pays, co-insurance and deductibles. The Program does not cover the costs of physician office visits or evaluations, blood work or other testing, or transportation.
- Eligible individuals must have commercial insurance coverage for CINQAIR. Uninsured and cash-paying individuals are NOT eligible for this Program nor are individuals with commercial insurance coverage that does not provide coverage for CINQAIR.
- Individuals enrolled in any state or federally funded healthcare program, including but not limited to, Medicare, Medicare Advantage Plans, Medicare Part D, Medicaid, Medigap, VA, DoD, TRICARE, and the Puerto Rico Government Health Insurance Plan are NOT eligible for this Program.
- Void if copied, transferred, purchased, altered or traded, and where prohibited and restricted by law
- Persons residing in the states of Massachusetts, Minnesota, Michigan and Rhode Island are eligible for financial assistance with their out-of-pocket costs for the drug only and are NOT eligible for other types of financial assistance (administration of the drug).
- Individuals who are Medicare eligible and enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees (i.e., you are eligible for Medicare Part D but receive a prescription drug benefit through a former employer) are NOT eligible for this Program.
- Patients who move from commercial to federally funded insurance will no longer be eligible for the Program.
- Eligible patients receive a maximum of \$10,000 in out-of-pocket assistance per calendar year, e.g., January 1 through December 31. A patient or a patient’s health care provider must submit a Program claim form and Explanation of Benefits from the patient’s commercial insurance plan detailing the patient’s out-of-pocket costs for CINQAIR and its administration to receive payment from the Program. Each eligible patient is responsible for their out-of-pocket costs for CINQAIR (reslizumab) and its administration above this amount. Patients enrolled in the Program will be automatically enrolled in the Program for the next calendar year unless they opt out of the Program or their insurance coverage changes.
- All coverage requirements mandated by the insurance company of the eligible patient must be satisfied in order for the Program to take effect. When submitting claims under this Program, patients and their treating providers are certifying that they understand the program rules, regulations and terms and conditions and comply with the Program terms as set forth herein. Specifically, you are certifying that a claim has not been submitted under a

state or federally funded healthcare program, including but not limited to, Medicare, Medicare Advantage Plans, Medicare Part D, Medicaid, Medigap, VA, DoD, TRICARE, and the Puerto Rico Government Health Insurance Plan.

- Teva Respiratory, LLC reserves the right to make eligibility determinations, to set Program benefit maximums, to monitor participation, and to change, rescind, revoke, or discontinue this Program at any time without notice. Limit one Program enrollment per individual. If you have any questions regarding this Program, your eligibility or benefits or if you wish to discontinue your participation, call the CINQAIR Cost Support Program at 1-844-838-2211 (9:00 am-7:00 pm ET, Monday-Friday).